No 04 2019

Diamyd Medical has outlined key learnings from the interim analysis of its Phase 3 DIAGNODE-3 trial, saying the findings may help inform future GAD65-based antigen-specific immunotherapy studies in recent-onset type 1 diabetes.

AstraZeneca reported continued growth in the first half of 2026 and said it remains on track to deliver on its ambition of USD 80 billion in total revenues by 2030.

The Board of Directors of Alligator Bioscience has resolved to discontinue further independent development of mitazalimab and to strategically refocus the company’s resources on the out-licensed HLX22 project.

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).

The Board of Directors and the CEO assess that having a consolidated management team on site in Uppsala, close to the core operations, will provide the best conditions for continuing to build the organization required for the next phase and for advancing development programs, the company states.

With an intended investment volume of more than EUR 200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision. 

The offer values PolyPeptide's equity at approximately CHF 1.46 billion.